As GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro gain popularity for weight loss, doctors are observing a ...
HealthDay News — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online January ...
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...
Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...
Hi there! If you’re here, chances are you’re on a GLP-1 medication like Ozempic, Wegovy, or Mounjaro, and you’re looking ...
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
About one in eight adults in the United States has tried or currently uses a GLP-1 medication, and a quarter of those users cite weight loss as their main goal. But weight loss doesn't discriminate ...